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D iscussion of the cost-effectiveness analysis of drug-eluting stents (DES) is both extremely important and necessary, although challenging. Perhaps this 
urgency contradicts what research has recently dem-
onstrated regarding such devices: the obvious clinical 
bene fit of DES in all analysed subgroups in randomised 
experimental scenarios and in real patients.1,2 This year 
marked the tenth anniversary of the use of this ground-
breaking technology in our field. Several studies have 
shown both the efficacy and safety of these devices for 
coronary restenosis reduction compared with bare-metal 
stents (BMS).3-5 Data favouring their use have led to 
increased deployment. Cardiologists must consider the 
novelty and high cost of this technology; conversely, they 
must consider the undeniable benefits it provides. The 
question must be asked: is this treatment cost-effective? 
See page 21
In the study published in this issue of the Revista 
Brasileira de Cardiologia Invasiva, Ferreira et al.6 
compared the performance of the Taxus® DES and the 
Liberté® BMS in consecutive, non-randomised patients. 
Even in countries where the DES/BMS relationship is 
not as heavily promoted as in this sample, and despite 
the reduction of restenosis with DES in all subgroups 
analysed, the development of a model of maximal 
benefits is necessary. In one of these recently published 
models,7 the number needed to treat (NNT) with DES to 
avoid new revascularisation of the target vessel ranged 
from 6 to 80. This finding means that in certain sub-
groups, restenosis with BMS was so low that it would 
be necessary to treat 80 patients with DES in order to 
avoid a new procedure. Conversely, in other subgroups, 
restenosis with BMS was high, and the NNT with DES 
to avoid a new procedure was only 6. These concepts 
generate a proper discussion regarding the moment 
at which a decision must be made, and the clinician 
must compare the clinical benefit of using a device 
versus public health policies in order to optimize the 
incorporation of new technologies.
The cost-effectiveness concept can be defined as 
the difference between the cost of the two interventions, 
expressed in monetary value, divided by the diffe rence 
between their effectiveness, expressed in years of life 
gained (life expectancy) or in order less important out-
comes, such as the number of prevented complications 
and the number of averted non-fatal events.8 Regarding 
BMS, the following question must be asked: what is the 
additional cost for each new averted revascularisation? 
In Brazil, the values obtained in order to avoid either 
a new revascularisation or an event in the target vessel 
were R$ 47,000 in the analysis by Polanczyk et al.,9 
R$ 131,000 in the analysis by Ferreira et et al.,10 and 
the incredible value of R$ 190,000 was obtained in the 
study by Quadros et al.11 Two variables influence these 
large figures, which are substantially higher than the 
US $1,650 was found in the North-American study by 
Cohen et al.12 These variables are the following: the 
low incidence of clinical restenosis with BMS, which 
is exactly what we have seen in a study published in 
this issue (consequently, a higher number of patients 
need to be treated with DES to avoid restenosis); and 
the high prices of both stents in addition to the high 
DES/BMS cost ratio, which is always greater than 3, 
or in absolute terms, with a price difference between 
the two of greater than R$ 8,000. 
In Ferreira et al.,6 we observe that the comparison 
was based on high figures, either that of DES (approxi-
mately R$ 11,000) or of BMS (approximately R$ 4,000 
– extremely expensive!). Despite the cost relationship 
between the two treatments, this has not been com-
monly observed by us.
A less relevant aspect of the proposed analysis, 
albeit considerable given the vision of utilising the 
best technology available, was the deployment of the 
Taxus® paclitaxel-elutant stent. This is a first-generation 
© 2012 Elsevier Editora Ltda. and Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. All rights reserved.
Feres et al.
A Simple Question with a Multivariate Answer
Rev Bras Cardiol Invasiva. 
2012;20(1):11-2
12
DES that has yielded inferior results compared to those 
of the second-generation stents.13 
Ferreira et al.6 used an observational, non-randomised, 
consecutive design, whose results were not monitored 
or even adjudicated by an independent external com-
mittee. Data are analysed under such considerations.
In an observational, non-randomised study, vari-
ables evaluated before performing an intervention that 
is under analysis and non-modifiable or non-affected 
variables are called covariants.
The propensity score14 is a method that seeks to 
balance these covariants to provide independence to 
the analysed variable. In other words, this method 
evaluates the impact selection bias over the effect of 
the treatment. This tool is applied in the beginning 
of the analysis, and has an effect similar to that of 
multivariate analysis deployed by regression, moving 
backwards from the events to its determinants.
This score subsequently provides a ‘randomisation’ 
effect for the known variables. It is limited by the 
unknown covariants, which are not included in the 
analysis. Its use does not preclude the specification 
of the suggested analyses or the sample calculation 
regarding the power and precision of the tool.
That study proposes a comparison of the two 
interventions that cannot be randomised due to ethi-
cal issues. Therefore, covariant control tools, such as 
propensity score, are useful.
The results presented so far qualify only as hy-
pothesis generators due to the weakness imposed by 
the selection bias.
The authors comment about this limitation, which 
is inherent to the propensity score.
It must also noted that, even within this environ-
ment, sample calculation is fundamental to establish 
sample power and precision. That is, in considering 
the balancing capacity of the propensity score, does 
the sample size allow for the denial of null hypothesis? 
Therefore, in this issue, more information is provided 
to the literature to judge a complex theme. Its interpreta-
tion deserves consideration regarding the study design, 
the selection bias attenuation method the DES type used, 
and the cost relationship between the two types of stents, 
before absolute conclusions can be reached. 
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